CRISPR Therapeutics (NASDAQ:CRSP) Research Coverage Started at Rodman & Renshaw

Rodman & Renshaw started coverage on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report published on Friday morning, Marketbeat.com reports. The firm issued a buy rating and a $90.00 price target on the stock.

A number of other brokerages have also issued reports on CRSP. Barclays dropped their price objective on shares of CRISPR Therapeutics from $80.00 to $67.00 and set an equal weight rating for the company in a report on Thursday, May 9th. Oppenheimer lowered their price target on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an outperform rating for the company in a report on Friday, May 10th. Robert W. Baird raised their price target on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the stock a neutral rating in a report on Thursday, May 9th. Needham & Company LLC restated a buy rating and set a $88.00 price target on shares of CRISPR Therapeutics in a report on Thursday, June 27th. Finally, Wells Fargo & Company lowered their price target on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an equal weight rating for the company in a report on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat, CRISPR Therapeutics currently has an average rating of Hold and a consensus price target of $73.31.

CRISPR Therapeutics Stock Down 0.3 %

CRSP traded down $0.16 during trading hours on Friday, hitting $49.50. 1,021,410 shares of the company’s stock were exchanged, compared to its average volume of 1,598,862. The stock’s 50-day moving average is $57.20 and its two-hundred day moving average is $63.27. CRISPR Therapeutics has a 1-year low of $37.55 and a 1-year high of $91.10. The stock has a market cap of $4.20 billion, a price-to-earnings ratio of -18.44 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Monday, August 5th. The company reported ($1.49) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.06). The firm had revenue of $0.52 million for the quarter, compared to the consensus estimate of $12.31 million. During the same quarter in the previous year, the firm earned ($0.98) earnings per share. CRISPR Therapeutics’s revenue for the quarter was down 99.3% on a year-over-year basis. On average, equities research analysts anticipate that CRISPR Therapeutics will post -5.52 EPS for the current year.

Insider Activity at CRISPR Therapeutics

In related news, COO Julianne Bruno sold 3,366 shares of the business’s stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $56.09, for a total transaction of $188,798.94. Following the completion of the transaction, the chief operating officer now directly owns 6,745 shares in the company, valued at approximately $378,327.05. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in CRISPR Therapeutics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,538,725 shares of the company’s stock worth $69,843,000 after purchasing an additional 7,635 shares in the last quarter. Raymond James & Associates raised its holdings in shares of CRISPR Therapeutics by 11.3% during the 4th quarter. Raymond James & Associates now owns 31,839 shares of the company’s stock worth $1,993,000 after acquiring an additional 3,231 shares in the last quarter. Raymond James Financial Services Advisors Inc. raised its holdings in shares of CRISPR Therapeutics by 18.1% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 39,417 shares of the company’s stock worth $2,468,000 after acquiring an additional 6,039 shares in the last quarter. Blue Trust Inc. purchased a new stake in shares of CRISPR Therapeutics during the 4th quarter worth approximately $32,000. Finally, Global Retirement Partners LLC raised its holdings in shares of CRISPR Therapeutics by 46.8% during the 4th quarter. Global Retirement Partners LLC now owns 2,275 shares of the company’s stock worth $144,000 after acquiring an additional 725 shares in the last quarter. 69.20% of the stock is currently owned by institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.